Verona Pharma plc Share Price London S.E.
Equities
VRP
GB00BYW2KH80
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
55 GBX | +5.77% | +4.76% | -11.29% |
Sales 2024 * | 15.35M 19.17M 1.53B | Sales 2025 * | 103M 129M 10.33B | Capitalization | 1.01B 1.26B 101B |
---|---|---|---|---|---|
Net income 2024 * | -83M -104M -8.3B | Net income 2025 * | -38M -47.46M -3.8B | EV / Sales 2024 * | 53.6 x |
Net cash position 2024 * | 184M 230M 18.39B | Net cash position 2025 * | 146M 183M 14.64B | EV / Sales 2025 * | 8.32 x |
P/E ratio 2024 * |
-24.1
x | P/E ratio 2025 * |
-81.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.42% |
Latest transcript on Verona Pharma plc
1 day | +5.77% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 59 | 31/01/20 | |
Mark Hahn
DFI | Director of Finance/CFO | 61 | 29/02/20 |
Kavita Aggarwal
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mahendra Shah
BRD | Director/Board Member | 79 | 16/06/16 |
Vikas Sinha
BRD | Director/Board Member | 60 | 11/09/16 |
David Ebsworth
CHM | Chairman | 69 | 30/11/14 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- VRNA Stock
- VRP Stock